Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Rezolute ( (RZLT) ) is now available.
On March 24, 2026, Rezolute reported outcomes from a March 17 in-person Type B FDA meeting regarding sunRIZE, its Phase 3 trial of ersodetug in congenital hyperinsulinism, after the study previously failed to meet its primary endpoint in December 2025 despite reductions in hypoglycemia events. The company highlighted clinically meaningful continuous glucose monitoring improvements, pharmacologic activity and encouraging open-label extension data, and, following FDA acknowledgment of trial-design challenges, was encouraged to submit full study reports and datasets for independent review that could determine whether a marketing application is viable or if further data will be required, with an update expected in the second half of 2026.
The FDA meeting focused on sunRIZE trial outcomes and behavioral factors that may have confounded hypoglycemia measurements, while still emphasizing the need for adequate and well-controlled evidence. Rezolute now plans to provide comprehensive data packages to support FDA’s independent assessment, a step that could materially influence the future of ersodetug in congenital HI and the availability of new treatment options for this underserved patient community.
The most recent analyst rating on (RZLT) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Rezolute stock, see the RZLT Stock Forecast page.
Spark’s Take on RZLT Stock
According to Spark, TipRanks’ AI Analyst, RZLT is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn) and a bearish technical setup (price below major moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend, while the latest corporate update adds uncertainty after a Phase 3 miss despite some encouraging secondary observations and regulatory planning.
To see Spark’s full report on RZLT stock, click here.
More about Rezolute
Rezolute, Inc. is a late-stage rare disease biopharmaceutical company focused on treating hypoglycemia caused by hyperinsulinism (HI), including both congenital and tumor-related forms. Its lead antibody therapy, ersodetug, a fully human monoclonal antibody targeting the insulin receptor, is designed to be a universal treatment option across all forms of HI.
Average Trading Volume: 3,437,013
Technical Sentiment Signal: Sell
Current Market Cap: $229.7M
For detailed information about RZLT stock, go to TipRanks’ Stock Analysis page.